# BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

> **NCT03083691** · PHASE2 · COMPLETED · sponsor: **Lung Cancer Group Cologne** · enrollment: 90 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell Lung

## Interventions

- **DRUG:** Nivolumab, Ipilimumab
- **DRUG:** Nivolumab, Ipilimumab

## Key facts

- **NCT ID:** NCT03083691
- **Lead sponsor:** Lung Cancer Group Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-13
- **Primary completion:** 2022-08-31
- **Final completion:** 2023-11-20
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03083691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03083691, "BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03083691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*